logo-loader

Summit Therapeutics welcomes investment from US billionaire ahead of busy Q1

Published: 15:57 14 Jan 2019 GMT

Glyn Edwards, chief executive of Summit Therapeutics PLC (LON:SUMM), discusses with Proactive London's Andrew Scott the recent US$25mln investment in the company by US healthcare entrepreneur Robert Duggan.

Duggan was the chief executive and chairman of Pharmacyclics before it was sold to pharma giant AbbVie Inc (NYSE:ABBV) for US$21bn in 2015.

The purchase will take Duggan’s stake, which sat at just 0.2% before, to 48.8%.

Chesnara reports strong 2023 results with improved cash generation and...

Chesnara PLC (LSE:CSN) chief executive Steve Murray discusses the company's full-year results for 2023 with Proactive's Stephen Gunnion, describing them as strong and particularly highlighting £53 million in commercial cash generation and a dividend coverage of around 150%. The company has...

1 hour, 2 minutes ago